mrsa

Ceftobiprole medocaril (BAL5788), the parenteral prodrug of Ceftobiprole, is a broad-spectrum cephalosporin effective against Methicillin-resistant Staphylococcus aureus (MRSA).

Anti-MRSA agent 15 (Compound 9o10) exhibits antimicrobial activity, inhibiting methicillin-resistant Staphylococcus aureus (MRSA) with a minimum inhibitory concentration (MIC) of 0.0625 μg mL. It demonstrates low hemolytic activity and minimal cytotoxicity. Additionally, Anti-MRSA agent 15 shows anti-infection activity in mice.

Anti-MRSA agent 2 (compound 14) is a potent inhibitor of methicillin-resistant Staphylococcus aureus (MRSA) (MIC: 0.098 μg ml), exhibiting relatively low toxicity to normal cells. It strongly disrupts bacterial membranes and effectively binds to bacterial genomic DNA.

Anti-MRSA agent 4 (compound 7a), a selective and potent inhibitor of Gram-positive Methicillin-resistant Staphylococcus aureus (MRSA) growth, demonstrates a minimum inhibitory concentration (MIC) of ≤ 0.26 µM and exhibits neither cytotoxic nor hemolytic activity in HEK293 cells [1].

Anti-MRSA agent 1 is an MRSA inhibitor with an MIC value of 0.5 μg mL and is effective in alleviating the effects of MRSA resistance.

Anti-MRSA agent 3 inhibits methicillin-resistant Staphylococcus aureus (MRSA) activity significantly (MIC: 0.098 μg ml) with low toxicity to normal cells. anti-MRSA agent 3 has a high binding affinity for bacterial genomic DNA and a strong ability to disrupt bacterial cell walls and membranes.

Anti-MRSA agent 7 (Compound 12) is a potent antibacterial compound that effectively inhibits S. aureus and E. coli DNA gyrases, as well as topo IV enzymes from the same organisms, with IC50 values of 0.185 μM, 0.365 μM, 0.341 μM, and 0.059 μM, respectively [1].

Anti-MRSA agent 21 (Compound 27) demonstrates antibacterial activity against MRSA with a minimum inhibitory concentration (MIC) of 1 μM. It disrupts the bacterial cell membrane and increases reactive oxygen species.

Anti-MRSA agent 20 (Compound a4) is an antimicrobial agent targeting MRSA with a minimum inhibitory concentration (MIC) of less than 0.03125 μg mL. It binds to the peptidyl transferase center of the ribosome, inhibiting the synthesis of MRSA toxins and bacterial division, thereby suppressing bacterial survival. Furthermore, Anti-MRSA agent 20 significantly reduces the pulmonary MRSA load and diminishes lung damage in mice infected with MRSA (ED50= 6.48 mg kg).

Anti-MRSA agent is a potent antagonist of MRSA (MIC50: 0.38 μg mL) with low hERG activity (IC50: 40 μM). anti-MRSA agent also has low toxicity to mammalian cells and little potential to acquire bacterial resistance.

Anti-MRSA agent 24 (compound 6K) is an antibacterial compound that targets methicillin-resistant Staphylococcus aureus (MRSA), demonstrating significant inhibitory effects on strains resistant to penicillin.

Anti-MRSA agent 18 (E17) is an inhibitor of MRSA, exhibiting MIC values of 2 μg mL for S. aureus and 4 μg mL for MRSA. This compound accelerates bacterial death by interacting with the bacterial cell membrane constituents, phosphatidylglycerol and cardiolipin, leading to changes in membrane permeability and polarization. Additionally, it increases intracellular ROS, along with leakage of DNA and proteins.

Anti-MRSA agent 19 (Compound 1) is an antibiotic that exhibits activity against Staphylococcus aureus. It is active against 40 clinical isolates from the CDC, representing diverse bacterial species with various resistance factors, including resistance to vancomycin, aminoglycoside tetracycline, and oxazolidinone (median MIC=4 μg mL).

Anti-MRSA agent 6 (compound 3q6) is a potent anti-methicillin-resistant Staphylococcus aureus (anti-MRSA) agent with low cytotoxicity for MCF-7 and A549 cells [1].

Anti-MRSA agent 12 (Compound SM-5) is an antibiotic that exhibits antibacterial activity, with minimum inhibitory concentrations (MICs) of 7.81 μM for both Staphylococcus aureus and S. epidermidis, and 62.5 μM for Escherichia coli. Additionally, it inhibits methicillin-resistant S. aureus (MRSA) by preventing the formation of biofilms.

Anti-MRSA agent 16 (Compound 4) acts as an inhibitor against methicillin-resistant Staphylococcus aureus (MRSA). When used in combination with oxacillin or meropenem, it proves effective in treating infected mice.

Anti-MRSA agent 17 (8) acts as an inhibitor of S. aureus (MRSA) BPL (SaBPL), exhibiting a Ki value of 10.3 nM.

Anti-MRSA Agent 8 (Compound 7g), a derivative of DAPG, exhibits potent antibacterial properties by interacting with bacterial cell membranes and is useful for studying methicillin-resistant Staphylococcus aureus (MRSA) [1].

Anti-MRSA agent 22 (Compound 5a) is an effective antibacterial compound against MRSA with a minimum inhibitory concentration (MIC) of 6 µg mL. It exhibits high binding affinity to FabI, with a value of -11.19.

MRSA antibiotic 2 is an antibiotic compound effective against various Gram-positive bacteria, including B. subtilis, S. aureus, and methicillin-resistant S. aureus (MRSA).

Anti-MRSA agent 23 (compound 11) is a potent agent against methicillin-resistant Staphylococcus aureus. This compound exhibits both antibacterial and antibiofilm properties. It facilitates the healing and reconstruction of MRSA-infected skin wounds by reducing bacterial load, alleviating inflammation, and promoting angiogenesis.

Blasticidin S HCl is a peptide-based nucleoside antibiotic (antibiotic) isolated from Streptomyces griseochromogenes that inhibits prokaryotic and eukaryotic protein synthesis by interfering with the formation of peptide bonds in the ribosome.

Glycosyltransferase-IN-1 is a glycosyltransferase inhibitor with bacteriostatic activity, inhibiting MSSA, MRSA, Bacillus subtilis, and Enterobacteriaceae.

Alalevonadifloxacin is a DNA gyrase and DNA topoisomerase inhibitor and a novel antibacterial compound of the quinolone class targeting MRSa. Alalevonadifloxacin is potentially useful in the treatment of bacterial Gram-positive, Gram-negative and anaerobic infections.